pan>)--GenSpera, Inc. (OTCBB:GNSZ) announced that the Medications and Healthcare
products Regulatory Agency (MHRA) of the United Kingdom (Britain) has cleared
for initiation a Phase II human clinical trial of its lead substance,
G-202, in the treatment of prostate cancer sufferers who have failed
prior hormone imbalances therapy. The Phase II study, which was approved by the
United states of america (US) Food and Drug Administration in Come early july 2012, will be
conducted during up to six sites in the US and the UK and will join up to
40 patients having chemotherapy-nave, metastatic castrate-resistant
prostate cancer. GenSpera plans to initiate the UK study pending
clearance through the Multicentre Research Ethics Committee (MREC).
“This kind of authorization for GenSperas first medical trial outside of the
US is an important milestone for our company and underscores our
commitment to an international professional medical development program for G-202,
throughout parallel with the US program”,beats by dre outlet;
That authorization for GenSperas first clinical trial outside of the
US is an important motorola milestone for our company and emphasizes our
commitment to an international specialized medical development program for G-202,
within parallel with the US system, said Craig Dionne, PhD, GenSpera CEO
and President.
About GenSpera
GenSpera, Incorporated. is an oncology company focused on developing therapeutics
that have the potential to deliver a strong, unique and patented drug
directly to tumors. GenSperas technology platform combines a powerful,
plant-derived cytotoxin (thapsigargin) with a prodrug shipping and delivery system
that targets the release of the drug only inside tumor. Unlike
standard cancers drugs, thapsigargin has been shown to kill cells
independently of their division rate, which may provide an effective
method of kill fast- and slow-growing cancers and also cancer stem cells.
GenSpera offers completed a Phase Ia dose-escalation safety and
tolerability study with its guide drug candidate, G-202, at the Sidney
Kimmel Detailed Cancer Center at Johns Hopkins, your University of
Wisconsin Carbone Cancers Center, and the Cancer Treatment method and Research
Center on the University of Texas Wellbeing Science Center in Washington.
The study has continued into a Period Ib dose refinement study at this
same clinical sites. G-202 is cleared in the United States and
British isles for initiation of a multi-center Phase II trial in
patients with chemotherapy-nave, metastatic castrate-resistant prostate
cancer. GenSpera desires to initiate multiple Phase II trials of G-202
in lots of different types of cancer. The start of the Phase II
demos at each site is subject to your approval of their respective
Institutional Examine Board or Multicentre
Research Strength Committee.
For more information, please visit the Companys website: www.genspera.com.
Cautionary Record Regarding Forward Looking Data
This news release may contain forward-looking transactions,cheap beats by dre studio. Investors are
cautioned that such forward-looking statements in this pr release
regarding potential applications of GenSperas engineering constitute
forward-looking statements that involve dangers and uncertainties,
including, with out limitation, risks inherent in the growth and
commercialization of potential goods, uncertainty of clinical trial
outcomes or regulatory approvals and also clearances, need for future capital,
reliability upon collaborators and maintenance of our own intellectual
property rights. Actual results may differ materially from the effects
anticipated in these forward-looking statements. Additional information
on potential factors that might affect our results along with other risks and
uncertainties are going to be detailed from time to time in GenSperas occasional
reports filed with the Registration.
Information Source: Business Twine
September 1st, 2012 - 04:30pm
If you need further information just follow this:
没有评论:
发表评论